Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: To evaluate the efficacy and safety of the combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Fifty-four chemonaive patients with stage IIIB or IV NSCLC have been included, 44 males and 10 females, with a median age 63 years (range 19–75). Thirty-two (59%) patients had adenocarcinoma, 13 (24%) squamous cell, 1 (2%) large cell carcinoma and 8 (15%) others. Eight (15%) had stage IIIB and 46 (85%) stage IV. Treatment was consisted of 1,200 mg/m2 gemcitabine given as a 2-h continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle for every 21 days. A total of 223 chemotherapy cycles were administered, with a median of four cycles per patient (range 1–6), and 15 (28%) patients received all six cycles. Results: Of the 54 patients enrolled, all were evaluated for toxicity and 51 assessed for response. The overall response rate was 41% (95% confidence interval, 28–57%) with complete and partial responses of 4 and 37%, respectively. The median time to disease progression was 5.0 months (95% CI, 3.7–6.3 months), and median overall survival time was 11.5 months (95% CI, 9.9–13.1 months). One-year survival was 42%. The main grade 3–4 toxicity (according to the WHO scale) consisted of neutropenia (56%) and thrombocytopenia (57%). Patients were required platelet transfusion in 27 cycles (12%) and hematopoietic growth factors support care in 56 (25%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 6% and grade 1–2 skin rash occurred in 43%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable and tolerated, and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2005) Global Cancer Statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in Non-Small Cell Lung Cancer (1995) A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899–909

    Google Scholar 

  3. Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367

    PubMed  CAS  Google Scholar 

  4. Wozniak AJ, Crowley JJ, Balcerzak SP et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459–2465

    PubMed  CAS  Google Scholar 

  5. Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631

    PubMed  CAS  Google Scholar 

  6. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 18:122–130

    PubMed  CAS  Google Scholar 

  7. Crino L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522–3530

    PubMed  CAS  Google Scholar 

  8. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer Italian Lung Cancer Project. J Clin Oncol 20:4285–4291

    Article  PubMed  CAS  Google Scholar 

  9. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer Eastern Cooperative Oncology Group. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  10. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel pluscarboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210–3218

    PubMed  CAS  Google Scholar 

  11. Smit EF, van Meerbeeck JP, Lianes P et al (2003) Three-arm randomized study of two cisplatinbased regimens and paclitaxel plus gemcitabine in advanced non-smallcell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol 21:3909–3917

    Article  PubMed  CAS  Google Scholar 

  12. Le Chevalier T, Scagliotti G, Natale R et al (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80

    Article  PubMed  CAS  Google Scholar 

  13. Gandhi V, Plunkett W (1990) Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675–3680

    PubMed  CAS  Google Scholar 

  14. Plunkett W, Huang P, Xu Y et al (1995) Gemcitabine: metabolism, mechanisms of action, and self potentiation. Semin Oncol 22:3–10

    PubMed  CAS  Google Scholar 

  15. Grunewald R, Kantarjian H, Keating MJ et al (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823–6826

    PubMed  CAS  Google Scholar 

  16. Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498

    PubMed  CAS  Google Scholar 

  17. Grunewald R, Abbruzzese JL, Tarasoff P et al (1991) Saturation of 2′,2′-difluorodeoxycytidine 5′ triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258–262

    Article  PubMed  CAS  Google Scholar 

  18. Grunewald R, Kantarjian H, Du M et al (1992) Gemcitabine (2′,2′-difluorodeoxycytidine) in leukemia: a phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 10:406–413

    PubMed  CAS  Google Scholar 

  19. Tempero M, Plunkett W, Ruiz van Haperen V et al (2003) Randomized phase II comparison of dose intense Gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408

    Article  PubMed  CAS  Google Scholar 

  20. Schmid P, Akrivakis K, Flath B et al (1999) Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10:625–631

    Article  PubMed  CAS  Google Scholar 

  21. Touroutoglou N, Gravel D, Raber MN et al (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003–1008

    Article  PubMed  CAS  Google Scholar 

  22. Cortesi E, Barduagni M, Antimi M et al (2003) Prolonged gemcitabine infusion in non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98:337–343

    Article  PubMed  CAS  Google Scholar 

  23. Van Echo DA, Egorin MJ, Aisner J (1989) The pharmacology of carboplatin. Semin Oncol 16:1–6

    PubMed  Google Scholar 

  24. Carmichael J, Allerheiligen S, Walling J (1996) A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 23:55–59

    PubMed  CAS  Google Scholar 

  25. Ng EW, Sandler AB, Robinson L et al (1999) A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hosier Oncology Group study. Am J Clin Oncol 22:550–553

    Article  PubMed  CAS  Google Scholar 

  26. Carrato A, Garcia-Gomez J, Alberola V et al (1999) Carboplatin (carbo) in combination with gemcitabine (gem) in advanced non-small cell lung cancer (NSCLC): comparison of two consecutive phase II trials using different schedules. Proc Am Soc Clin Oncol 18:498

    Google Scholar 

  27. Parente B, Barrosa A, Conde S et al (2001) A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three versus a four-week schedule. Semin Oncol 28:10–14

    Article  PubMed  CAS  Google Scholar 

  28. Jovtis S, Brocato N, Balbiani L et al (1999) First-line therapy with gemcitabine (GEMTRO) (G) and carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II study. Proc Am Soc Clin Oncol 18:510

    Google Scholar 

  29. Sederholm C (2002) Gemcitabine (G) compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 21:1162

    Google Scholar 

  30. Gross C, Holiday D, Hampton J et al (1999) A combination therapy of gemcitabine (GEM) and carboplatin (CBDCA) in advanced stage non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 18:1955

    Google Scholar 

  31. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    PubMed  CAS  Google Scholar 

  32. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  33. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  34. Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41:321–331

    Article  PubMed  Google Scholar 

  35. Rudd RM, Gower NH,Spiro SG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIb or IV non–small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142–153

    Article  PubMed  CAS  Google Scholar 

  36. Soo RA, Lim HL, Wang LZ et al (2003) Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study. Cancer Chemother Pharmacol 52:153–158

    Article  PubMed  CAS  Google Scholar 

  37. Domine M, Estevez L, Leon A et al (2002) A phase II trial of a two hour infusion of gemcitabine with carboplatin for advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:225b

    Google Scholar 

  38. De Castro J, Lorenzo A, Morales S et al (2005) Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol 55:197–202

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    N. Xu, P. Shen, X. C. Zhang, L. F. Yu, H. Y. Bao, G. M. Shi, S. Huang, J. Chen, H. B. Mou & W. J. Fang

Authors
  1. N. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. C. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. F. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Y. Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. M. Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. B. Mou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W. J. Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to N. Xu or W. J. Fang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, N., Shen, P., Zhang, X.C. et al. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 59, 1–7 (2007). https://doi.org/10.1007/s00280-006-0237-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0237-2

Keywords

Search

Navigation